Browse Category

Rare Diseases News 15 October 2025 - 26 October 2025

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the

26 October 2025

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart

15 October 2025

Biotech Industry · Business Analysis · Mergers & Acquisitions · NASDAQ:AKRO · NASDAQ:OMER · NYSE:NVO · Pharma News · Rare Diseases

Go toTop